2025
Multi-ancestry genome-wide association meta-analysis of buprenorphine treatment response
Davis C, Khan Y, Crist R, Vickers-Smith R, Hartwell E, Gelernter J, Kampman K, Kember R, Le Moigne A, Laffont C, Kranzler H. Multi-ancestry genome-wide association meta-analysis of buprenorphine treatment response. Neuropsychopharmacology 2025, 1-8. PMID: 40328918, DOI: 10.1038/s41386-025-02117-z.Peer-Reviewed Original ResearchGenome-wide association studiesTreatment responseOpioid use disorderGenome-wide significant lociGWAS meta-analysesCross-ancestry meta-analysisClinical characteristicsGenome-wide association meta-analysisGenetic predictors of treatment responseMeta-analysisPresence of chronic painAssociation meta-analysisUse disorderPartial agonist buprenorphinePhenome-wide association analysisTreat opioid use disorderPredictors of treatment responseExtended-release buprenorphineMillion Veteran ProgramSignificant lociLead variantsCross-ancestryAssociation studiesOdds of treatment responseAssociation analysisCivil Rights Laws for People With Opioid Use Disorder in the Emergency Department.
South A, Hawk K, Friedman S, Lofwall M, Fanucchi L, Cohen S. Civil Rights Laws for People With Opioid Use Disorder in the Emergency Department. Journal Of Addiction Medicine 2025 PMID: 40125857, DOI: 10.1097/adm.0000000000001480.Peer-Reviewed Original ResearchCivil rights lawsRights lawFederal civil rights lawOpioid use disorderLegal advocacyLegal liabilityUse disorderEmergency departmentAdoption of evidence-based practicesLawHealth care facilitiesHealth care systemEvidence-based practiceTreat opioid use disorderEvidence-based medicationsFatal overdoseRisk of deathOverdose crisisCare facilitiesCare systemEmergency cliniciansOutpatient treatmentEngage peopleLiabilityMedicationMedications for opioid use disorder in traditional medicare beneficiaries: associations with age
Ganz D, Lai J, Cantor J, Agniel D, Simon K, Stein B, Taylor E. Medications for opioid use disorder in traditional medicare beneficiaries: associations with age. Health Affairs Scholar 2025, 3: qxaf036. PMID: 40040649, PMCID: PMC11878533, DOI: 10.1093/haschl/qxaf036.Peer-Reviewed Original ResearchOpioid use disorderMOUD initiationIndex eventUse disorderTreat opioid use disorderAssociated with female sexRates of opioid use disorderIncreasing comorbidity scoreMultivariate logistic regressionAssociated with ageComorbidity scoreMedicare beneficiariesFemale sexOlder adultsAge-specific strategiesIncreased uptakeLogistic regressionOlder ageTraditional Medicare beneficiariesMOUDClaims dataMedication
2024
Four targets: an enhanced framework for guiding causal inference from observational data
Lu H, Li F, Lesko C, Fink D, Rudolph K, Harhay M, Rentsch C, Fiellin D, Gonsalves G. Four targets: an enhanced framework for guiding causal inference from observational data. International Journal Of Epidemiology 2024, 54: dyaf003. PMID: 39868475, PMCID: PMC11769716, DOI: 10.1093/ije/dyaf003.Peer-Reviewed Original ResearchHow Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice?
Edens E, Garcia Vassallo G, Heimer R. How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? The AMA Journal Of Ethic 2024, 26: e551-561. PMID: 38958424, DOI: 10.1001/amajethics.2024.551.Peer-Reviewed Original ResearchConceptsTreat opioid use disorderOpioid use disorderPrescribed long-term opioid therapyLong-term opioid therapyOpioid prescribing policiesOpioid therapyPrescribed opioidsOpioid prescribingUse disorderOpioidClinical practicePainPrescribing policiesDiagnostic categoriesClinical frameworkPrescribingPolitical reasonsTherapyAccess to treatment before and after Medicare coverage of opioid treatment programs
Liu R, Beetham T, Newton H, Busch S. Access to treatment before and after Medicare coverage of opioid treatment programs. Health Affairs Scholar 2024, 2: qxae076. PMID: 38938273, PMCID: PMC11210307, DOI: 10.1093/haschl/qxae076.Peer-Reviewed Original ResearchTreatment servicesOpioid use disorderTreatment programsOpioid treatment programsMedicare coverageFor-profit statusCounty-level changesTreat opioid use disorderNonwhite residentsNonwhite populationsOpioid use disorder treatment servicesSociodemographic characteristicsNational DirectoryServicesUse disorderTreatment facilitiesOutpatient settingMedicareAccessOpioidTrends in the Prescribing of Buprenorphine for Opioid Use Disorder, 2019-2023
Savitz S, Stevens M, Nath B, D’Onofrio G, Melnick E, Jeffery M. Trends in the Prescribing of Buprenorphine for Opioid Use Disorder, 2019-2023. Mayo Clinic Proceedings Innovations Quality & Outcomes 2024, 8: 308-320. PMID: 38841599, PMCID: PMC11152959, DOI: 10.1016/j.mayocpiqo.2024.04.004.Peer-Reviewed Original ResearchOpioid use disorderTreat alcohol use disorderAlcohol use disorderUse disorderX-waiverMedicare Advantage enrolleesTreat opioid use disorderRate ratiosEvaluate trendsPrescribing of buprenorphineOptumLabs Data WarehouseDaily doseCommercial enrolleesCoronavirus diseasePrescription fillsBuprenorphineDays supplyBuprenorphine prescribingFilling patternBuprenorphine accessImprove buprenorphine accessStudy periodResponse to coronavirus diseasePrescriber typePrescribing“They make it too hard and too many hoops to jump”: system and organizational barriers to drug treatment during epidemic rates of opioid overdose
Dickson-Gomez J, Krechel S, Ohlrich J, Montaque H, Weeks M, Li J, Havens J, Spector A. “They make it too hard and too many hoops to jump”: system and organizational barriers to drug treatment during epidemic rates of opioid overdose. Harm Reduction Journal 2024, 21: 52. PMID: 38413972, PMCID: PMC10900746, DOI: 10.1186/s12954-024-00964-5.Peer-Reviewed Original ResearchConceptsOpioid use disorderDrug treatmentImprove treatment retentionTreat opioid use disorderAttended group treatmentOpioid overdoseMedically managed withdrawalHeightened risk of overdoseRates of opioid overdoseCourse of treatmentTreatment retentionGroup treatmentUse disorderRisk of overdoseTreatment participationAbstinence requirementRespiratory depressionManaged withdrawalOpioidInitiate MOUDMOUD initiationMOUD stigmaMOUD treatmentHeightened riskOpioid overdose crisis
2023
Evaluation and guide for embedding opioid use disorder education in health professions’ curricula
Salvador J, Bolaños-Sacoman S, Katzman J, Morrison A, Fox L, Schneider J, Bhatt S, Kincaid T, Waldorf V. Evaluation and guide for embedding opioid use disorder education in health professions’ curricula. BMC Medical Education 2023, 23: 135. PMID: 36859298, PMCID: PMC9975819, DOI: 10.1186/s12909-023-04088-5.Peer-Reviewed Original ResearchConceptsOpioid use disorderPhysician assistantsTreat opioid use disorderLack of provider knowledgeUse disorderImprove knowledgePsychiatric nurse practitionersHealth professions curriculaPre-licensure learnersPost-graduationNurse practitionersProvider knowledgeBuprenorphine treatmentWaiver trainingShadowing opportunitiesTreatment to personsDisorder educationShadowing experienceExperiential trainingPositive overallOverdose deathsPhysiciansIncreased confidenceHealth crisisCOVID-19 pandemic
2022
Heroin Regulates Orbitofrontal Circular RNAs
Floris G, Gillespie A, Zanda M, Dabrowski K, Sillivan S. Heroin Regulates Orbitofrontal Circular RNAs. International Journal Of Molecular Sciences 2022, 23: 1453. PMID: 35163373, PMCID: PMC8836038, DOI: 10.3390/ijms23031453.Peer-Reviewed Original ResearchConceptsHeroin self-administrationOrbitofrontal cortexOpioid use disorderNeurobiological adaptationsSelf-AdministrationSelf-administer sucroseChronic heroin exposureRat orbitofrontal cortexOpioid-seeking behaviorTreat opioid use disorderHeroin exposureUse disorderBrain regionsOpioid heroinBehavioral responsesMale ratsFemale ratsHeroinSeeking behaviorDrug overdose deathsRatsOverdose deathsOpioidRNA splice variantsCortex
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply